Open AccessEquibalancing immune‐related adverse events and anticancer activity of immune checkpoint inhibitors
Author(s) -
Seeruttun Sharvesh Raj
Publication year - 2019
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.13180
Subject(s) - atezolizumab , nivolumab , pembrolizumab , durvalumab , immune system , ipilimumab , medicine , avelumab , immune checkpoint , cytotoxic t cell , cancer research , immunotherapy , immunology , biology , in vitro , biochemistry